Neurocognitive performance after PCSK9 inhibitor therapy: Current state of the evidence

Neurocognitive performance after PCSK9 inhibitor therapy: Current state of the evidence Hypercholesterolemia is one of the principal promoters of the atherosclerotic plaque genesis (Steinberg, ), representing a relevant cardiovascular (CV) risk factor (Mozaffarian et al., ). Therefore, a goal of primary and secondary prevention of CV diseases is the reduction of low‐density lipoprotein (LDL) cholesterol levels (National Cholesterol Education Program [NCEP] Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults [Adult Treatment Panel III], ). In this context, the use of statins as lipid‐lowering drugs has been, until now, a key step in reducing the CV risk (Naci et al., ; Taylor, Huffman, & Ebrahim, ); however, a new class of lipid‐lowering drugs that significantly reduce the levels of LDL cholesterol has recently emerged: the inhibitors of proprotein convertase subtilisin/kexin type 9 (PCSK9) (Giugliano & Sabatine, ; Gouni‐Berthold & Berthold, ; Sahebkar, Chew, & Watts, ; Sahebkar & Watts, ). PCSK9 is a protein that interacts with the LDL receptor (LDLR) favoring early degradation and preventing recycling. Monoclonal antibodies against PCSK9 increase the hepatic gene expression of LDLR, resulting in a pronounced cholesterol‐lowering effect caused by the LDL internalization processes.However, despite the enthusiasm generated by the efficacy of such drugs in lowering LDL cholesterol (Canevari & http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Neuroscience Research Wiley

Neurocognitive performance after PCSK9 inhibitor therapy: Current state of the evidence

Loading next page...
 
/lp/wiley/neurocognitive-performance-after-pcsk9-inhibitor-therapy-current-state-I6WvbA9Nwg
Publisher
Wiley
Copyright
© 2018 Wiley Periodicals, Inc.
ISSN
0360-4012
eISSN
1097-4547
D.O.I.
10.1002/jnr.24199
Publisher site
See Article on Publisher Site

Abstract

Hypercholesterolemia is one of the principal promoters of the atherosclerotic plaque genesis (Steinberg, ), representing a relevant cardiovascular (CV) risk factor (Mozaffarian et al., ). Therefore, a goal of primary and secondary prevention of CV diseases is the reduction of low‐density lipoprotein (LDL) cholesterol levels (National Cholesterol Education Program [NCEP] Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults [Adult Treatment Panel III], ). In this context, the use of statins as lipid‐lowering drugs has been, until now, a key step in reducing the CV risk (Naci et al., ; Taylor, Huffman, & Ebrahim, ); however, a new class of lipid‐lowering drugs that significantly reduce the levels of LDL cholesterol has recently emerged: the inhibitors of proprotein convertase subtilisin/kexin type 9 (PCSK9) (Giugliano & Sabatine, ; Gouni‐Berthold & Berthold, ; Sahebkar, Chew, & Watts, ; Sahebkar & Watts, ). PCSK9 is a protein that interacts with the LDL receptor (LDLR) favoring early degradation and preventing recycling. Monoclonal antibodies against PCSK9 increase the hepatic gene expression of LDLR, resulting in a pronounced cholesterol‐lowering effect caused by the LDL internalization processes.However, despite the enthusiasm generated by the efficacy of such drugs in lowering LDL cholesterol (Canevari &

Journal

Journal of Neuroscience ResearchWiley

Published: Jan 1, 2018

Keywords: ; ; ; ;

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off